3rd Annual Jefferson Urology Symposium: Men’s Health Forum

© The Canadian Journal of Urology TM : International Supplement, August 2020 20. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172(2): 658-663. 21. Buvat J, Montorsi F, Maggi M et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8(1):284-293. 22. Boloña ER, Uraga MV, Haddad RM et al. Testosterone use in men with sexual dysfunction: a systematic review and meta- analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82(1):20-28. 23. Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR, Osborn DE. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991;8(10):964-967. 24. LeeM, Sharifi R. Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails. Drugs Aging 2018;35(3):175-187. 25. Liu C, Lopez DS, ChenM, Wang R. Penile rehabilitation therapy following radical prostatectomy: ameta-analysis. J SexMed 2017; 14(12):1496-1503. 26. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001; 28(2):335-341. 27. Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. Sex Med Rev 2015;3(1):11-23. 28. Heaton JP, Lording D, Liu SN et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13(6):317-321. 29. AlexandreB,LemaireA,DesvauxP,AmarE.Edpharmacotherapy: Intracavernous injections of prostaglandin E1 for erectile dysfunction: Patient satisfaction and quality of sex life on long- term treatment. J Sex Med 2007;4(2):426-431. 30. Porst H. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience. J Urol 1996;155(3): 802-815. 31. Baniel J, Israilov S, Engelstein D, Shmueli J, Segenreich E, Livne PM. Three-year outcome of a progressive treatment program for erectile dysfunctionwith intracavernous injections of vasoactive drugs. Urology 2000;56(4):647-652. 32. Chung, E. Translating penile erectile hydraulics to clinical application in inflatable penile prosthesis implant. Curr SexHealth Rep 2017;9:84-89. 33. Dick B, Tsambarlis P, Reddy A, Hellstrom WJ. An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Rev Med Devices 2019;16(4): 281-286. 34. Carson CC 3rd, Mulcahy JJ andHarschMR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of follow up. J Urol 2011; 185(2):614-618. 35. Trost LW, Munarriz R, Wang R, Morey A, Levine L. External mechanical devices andvascular surgery for erectile dysfunction. J Sex Med 2016;13(11):1579-1617. 36. Li H, Matheu MP, Sun F, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. J Sex Med 2016;13(1):22-32. 37.Wang B, Ning H, Reed-Maldonado AB et al. Low- intensity extracorporeal shock wave therapy enhances brain-derived neurotrophic factor expression through PERK/ATF4 signaling pathway. Int J Mol Sci 2017;18(2):433. 38. Vardi Y, Appel B, Kilchevsky A et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double- blind, sham controlled study. J Urol 2012;187(5):1769-1775. 39. Kitrey ND, Gruenwald I, Appel B et al. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 2016;195(5):1550-1555. 40. Vardi Y, Appel B, Jacob G et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58(2):243-248. 41. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011;9(1):11-15. 42. Qiu, X, Sun C, Yu W et al. Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for treatment of diabetes- associated erectile dysfunction. J Androl 2012;33(1):37-44. 43. Ning H, Liu G, Lin G, Yang R, Lue TF, Lin CS. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue- derived stem cells. J Sex Med 2009;6(4):967-979. 44. Kim IG, Piao S, Lee JY. Effect of an adipose-derived stem cell and nerve growth factor-incorporated hydrogel on recovery of erectile function in a rat model of cavernous nerve injury. Tissue Eng Part A 2013;19(1-2):14-23. 45. KimSJ, Park SH, SungYC, KimSW. Effect of mesenchymal stem cells associated to matrixen on the erectile function in the rat model with bilateral cavernous nerve crushing injury. Int Braz J Urol 2012;38(6):833-841. 46. Qiu X, Villalta J, Ferretti L et al. Effects of intravenous injection of adipose-derived stemcells in a rat model of radiation therapy- induced erectile dysfunction. J Sex Med 2012;9(7):1834-1841. 47. Yiou R, Hamidou L, Birebent B et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol 2016;69(6):988-991. 48. Levy JA, Marchand M, Iorio L et al. Determining the feasibility of managing erectile dysfunction in humans with placental- derived stem cells. J Am Osteopath Assoc 2016;116(1):e1-5. 49. Scott S, RobertsM, ChungE. Platelet-richplasma and treatment of erectile dysfunction: critical reviewof literature and global trends in platelet-rich plasma clinics. Sex Med Rev 2019;7(2):306-312. 50. Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol 2018;59(1):61-65. 51. Epifanova MV, Chalyi ME, Krasnov AO. Investigation of mechanisms of action of growth factors of autologous platelet- rich plasma used to treat erectile dysfunction. Urologiia 2017;4:46-48. 52. Epifanova MV, Gvasalia BR, Durashov MA et al. Platelet- rich plasma therapy for male sexual dysfunction: myth or reality? Sex Med Rev 2020;8(1):106-113. 53. Campbell JD, Burnett AL. Neuroprotective and nerve regenerative approaches for treatment of erectile dysfunction after cavernous nerve injury. Int J Mol Sci 2017;18(8):1794. 54.Wu CC, Wu YN, Ho HO et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med 2012;9(11):2838-2848. 55. Ding XG, Li SW, Zheng XM et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 2009;11(2):215-221. 56. Ding XG, Li SW, Zheng XM et al. Effect of platelet-rich plasma on the regeneration of cavernous nerve: Experiment with rats. Zhonghua Yi Xue Za Zhi 2008;88(36):2578-2580. 57. Miller LE, Parrish WR, Roides B et al. Efficacy of platelet-rich plasma injections for symptomatic tendinopathy: Systematic review and meta-analysis of randomised injection-controlled trials. BMJ Open Sport Exerc Med 2017;3(1):e000237. 58. U.S. Patent and Trademark Office. Serial number 86395530 Reg. Number 4820964. Available at: https://www.uspto.gov . Accessed August 6, 2018. 35 The medical and surgical treatment of erectile dysfunction: a review and update